Search Results - "Strohmaier, Christine"

A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease by Nakamura, Yu, Strohmaier, Christine, Tamura, Kaoru, Kataoka, Naoko, Nakano, Masayuki, Oda, Shoichiro, Nishimura, Kazuma, Homma, Akira

“…Aim: To investigate whether 1-step titration of the rivastigmine patch (initiated at 5 cm 2 and titrated to 10 cm 2 after 4 weeks) is well tolerated in…”
Get full text

BGG 492 as an adjunctive treatment in patients with partial‐onset seizures: A 12‐week, randomized, double‐blind, placebo‐controlled, phase II dose‐titration study with an open‐label extension by Elger, Christian E., Hong, Seung Bong, Brandt, Christian, Mancione, Linda, Han, Jackie, Strohmaier, Christine

“…Summary Objectives To evaluate dose–response relationship of BGG 492 as add‐on therapy to 1–3 antiepileptic drugs in patients with partial‐onset seizures and…”
Get full text

BGG492 as an adjunctive treatment in patients with partial‐onset seizures: A 12‐week, randomized, double‐blind, placebo‐controlled, phase II dose‐titration study with an open‐label extension by Elger, Christian E., Hong, Seung Bong, Brandt, Christian, Mancione, Linda, Han, Jackie, Strohmaier, Christine

“…Summary Objectives To evaluate dose–response relationship of BGG492 as add‐on therapy to 1–3 antiepileptic drugs in patients with partial‐onset seizures and to…”
Get full text

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease by Cummings, Jeffrey, Froelich, Lutz, Black, Sandra E, Bakchine, Serge, Bellelli, Giuseppe, Molinuevo, José L, Kressig, Reto W, Downs, Pamela, Caputo, Angelika, Strohmaier, Christine

“…Determine whether patients with Alzheimer's disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5…”
Get more information

Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study by Emre, Murat, Poewe, Werner, De Deyn, Peter Paul, Barone, Paolo, Kulisevsky, Jaime, Pourcher, Emmanuelle, van Laar, Teus, Storch, Alexander, Micheli, Federico, Burn, David, Durif, Frank, Pahwa, Rajesh, Callegari, Francesca, Tenenbaum, Nadia, Strohmaier, Christine

“…This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with…”
Get full text

P1‐298: Tolerability, safety, and efficacy of the 1‐step titration scheme of rivastigmine patch 10 cm2 in japanese patients with mild‐to‐moderate Alzheimer's disease: A 24‐week randomized controlled study by Nakamura, Yu, Strohmaier, Christine, Shimozawa, Makoto, Kataoka, Naoko, Nakano, Masayuki, Oda, Shoichiro, Nishimura, Kazuma, Homma, Akira

Get full text

P1‐298: Tolerability, safety, and efficacy of the 1‐step titration scheme of rivastigmine patch 10 cm 2 in japanese patients with mild‐to‐moderate Alzheimer's disease: A 24‐week randomized controlled study by Nakamura, Yu, Strohmaier, Christine, Shimozawa, Makoto, Kataoka, Naoko, Nakano, Masayuki, Oda, Shoichiro, Nishimura, Kazuma, Homma, Akira

Get full text

Tolerability, safety, and efficacy of the 1-step titration scheme of rivastigmine patch 10 cm2 in japanese patients with mild-to-moderate Alzheimer’s disease: A 24-week randomized controlled study by Nakamura, Yu, Strohmaier, Christine, Shimozawa, Makoto, Kataoka, Naoko, Nakano, Masayuki, Oda, Shoichiro, Nishimura, Kazuma, Homma, Akira

Get full text

P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY by Molinuevo, José L., Cummings, Jeffrey, Frolich, Lutz, Galvin, James E., Krahnke, Tillmann, Strohmaier, Christine

Get full text

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24‐week, Randomized, Double‐Blind Parallel‐Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily) by Zhang, Zhen‐Xin, Hong, Zhen, Wang, Yan‐Ping, He, Li, Wang, Ning, Zhao, Zhong‐Xin, Zhao, Gang, Shang, Lan, Weisskopf, Marianne, Callegari, Francesca, Strohmaier, Christine

“…Summary Aims To compare the once‐daily rivastigmine patch 9.5 mg/24 h (10 cm2) versus twice‐daily capsule (12 mg/day) in Chinese patients with probable…”
Get full text

UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY by Molinuevo, José L, Cummings, Jeffrey, Frolich, Lutz, Galvin, James E, Krahnke, Tillmann, Strohmaier, Christine

Get full text

Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study by Molinuevo, Jose Luis, Grossberg, George, Frölich, Lutz, Galvin, James, Krahnke, Tillmann, Strohmaier, Christine

Get full text

P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study by Cummings, Jeffrey, Bellelli, Giuseppe, Black, Sandra, Bakchine, Serge, Krahnke, Tillmann, Strohmaier, Christine

Get full text

The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study by Cummings, Jeffrey, Bellelli, Giuseppe, Black, Sandra, Bakchine, Serge, Krahnke, Tillmann, Strohmaier, Christine

Get full text

P3–275: Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study by Molinuevo, Jose Luis, Grossberg, George, Frölich, Lutz, Galvin, James, Krahnke, Tillmann, Strohmaier, Christine

Get full text

Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease by Grossberg, George, Cummings, Jeffrey, Frölich, Lutz, Bellelli, Giuseppe, Molinuevo, José L., Krahnke, Tillmann, Strohmaier, Christine

“…Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD)…”
Get full text

P3‐424: High‐dose 13.3 mg/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis by Cummings, Jeffrey, Grossberg, George, Alva, Gustavo, Caputo, Angelika, Downs, Pamela, Strohmaier, Christine

Get full text

High-dose 13.3 mg/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis by Cummings, Jeffrey, Grossberg, George, Alva, Gustavo, Caputo, Angelika, Downs, Pamela, Strohmaier, Christine

Get full text

Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time-to-meet decline by Black, Sandra, Bakchine, Serge, Bellelli, Giuseppe, Molinuevo, Jose Luis, Downs, Pamela, Caputo, Angelika, Strohmaier, Christine

Get full text

Comparisons of patient characteristics in subpopulations of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study by Frolich, Lutz, Monsch, Andreas, Kressig, Reto, Downs, Pamela, Caputo, Angelika, Strohmaier, Christine

Get full text